Using bioceramic materials to repair bone defects
Clinical Study of Bioceramic Materials in Bone Defect Repair
This study is testing if a new type of bioceramic implant can help people heal better from bone defects compared to a standard bone implant.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 10 (estimated) |
| Ages | 18 Years to 65 Years |
| Sex | All |
| Sponsor | Nanjing First Hospital, Nanjing Medical University Academic / other |
| Locations | 1 site (Nanjing, Jiangsu) |
| Trial ID | NCT06249906 on ClinicalTrials.gov |
What this trial studies
This study aims to evaluate the effectiveness of bioceramic implants, specifically β-tricalcium phosphate, in repairing human bone defects. It will explore how the controlled microstructure of these implants can enhance bone regeneration, accelerate recovery, and improve overall bone quality. Participants will be divided into groups receiving either a commercial bone implant or a micro-structured bioceramic implant to assess the outcomes of each approach.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18-65 with no history of allergies and who can communicate effectively with the research team.
Not a fit: Patients with severe cardiopulmonary diseases, cognitive impairments, or those with acute infections may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved healing and recovery for patients with various bone injuries and conditions.
How similar studies have performed: Other studies have shown promising results with bioceramic materials in bone repair, indicating a potential for success in this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Patients who voluntarily take the test and sign the informed consent form; 2. Patients aged 18-65 years old with no history of allergies; 3. Patients able to communicate well with the investigator and follow the requirements of the entire trial. Exclusion Criteria: 1. Patients who refuse to sign the informed consent form to participate in the trial; 2. Patients who are not in the age range of 18 to 65 years; 3. Patients with diseases unsuitbale for the trial: history of allergies, severe cardiopulmonary disease, coagulation dysfunction, Alzheimer's disease, cerebral atrophy, acute phase or sequelae of cerebrovascular disease, cognitive impairment; 4. Patients in the acute phase of local or systemic bacterial infections; 5. Patients who cannot cooperate with the operation and evaluate the effect; 6. Other conditions that are considered inappropriate by the investigator to participate in the study.
Where this trial is running
Nanjing, Jiangsu
- Nanjing First Hospital — Nanjing, Jiangsu, China (Recruiting)
Study contacts
- Study coordinator: Qingqiang Yao, phD
- Email: yaoqingqiang@126.com
- Phone: 15366155699
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.